StockWatch
·

Procter & Gamble Health Ltd

BSE: 500126

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
386.38
+5.1%+17.1%
Expenditure
236.33
-12.6%+12.1%
Net Profit
111.51
+16.0%+25.9%
OPM %
39.84%
+3.71pp+2.82pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.00108.19216.37324.56432.75Q1 FY25Q2 FY25Q3 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

P&G Health Q2 FY27: Standalone PAT Up 26% YoY to ₹111.5 Cr, Margins Expand, Tops Own Preview Range

pharmaceuticals · margin expansion · standalone results

ResultsQ2 FY2702 Nov 20263 minPharma & Healthcare

Can PGHL Arrest Growth Slowdown Amid Raw Material Headwinds?

margin pressure · raw material costs · growth deceleration

Result previewQ2 FY2727 Oct 20263 minPharma & Healthcare

P&G Health Q1: revenue +7% YoY but core PAT down ~3% adjusted for one-off land-sale gain

pharmaceuticals · one-off gain · asset sale

ResultsQ1 FY2706 Aug 20263 minPharma & Healthcare
Latest
Board Meeting2 Nov, 2:44 pm

P&G Health Q2 FY27: Standalone PAT Up 26% YoY to ₹111.5 Cr, Margins Expand, Tops Own Preview Range

Procter & Gamble Health's standalone PAT for Q2 FY27 (quarter ended September 30, 2026) came in at ₹111.51 Cr, up 25.9% YoY from ₹88.54 Cr and up 16.0% QoQ from ₹96.15 Cr. Revenue from operations rose 17.7% YoY to ₹382.49 Cr (from ₹324.92 Cr) and 5.2% QoQ (from ₹363.71 Cr). This quarter carries no exceptional item, unlike Q1 FY27 which had a ₹31.80 Cr one-off gain on the sale of the Worli office property — so the YoY comparison (also clean of one-offs on the Q2 FY26 side) is the cleanest read, and it shows a genuinely strong, non-one-off print rather than a base-effect illusion. The margin story is operating leverage: total expenses grew only 12.1% YoY (₹210.85 Cr to ₹236.33 Cr) against 17.7% revenue growth, with cost of materials consumed actually flat-to-down and employee costs the main absolute increase. Net profit margin (PAT/total income) expanded to 28.9% from 26.8% a year ago and 26.2% last quarter — consistent expansion on both axes, pointing to price/mix holding up rather than the raw-material headwinds our pre-result preview had flagged as the key swing factor. Against our own pre-result preview — which pencilled in revenue of ₹350–365 Cr, an EBITDA margin watch of 26–27%, and normalized PAT growth of 8–12% off a soft Q1 (+7% revenue growth, margin pressure) — the actual print beats on every count: revenue above the range, and 25.9% YoY PAT growth roughly 2-3x the normalized growth the Street-thin preview had penciled in. The preview's watch items are resolved in the company's favour: revenue growth reaccelerated rather than stayed muted, and margins expanded rather than stayed under pressure. On the third watch item — full-year guidance — the company gives none on record, as before; management offers no formal outlook in this filing, consistent with its historical pattern of not guiding. A web search for hard analyst consensus specific to this print found none (PGHL has only sparse coverage, per the preview's own note of a single analyst rating), so vsStreet is marked unknown rather than inferred. No management press release/commentary beyond the regulatory filing was available to cross-check against print. The quarter's other corporate developments (trading window closure, AGM, director reappointment, dividend record date) are governance/calendar items unrelated to the operating print.

2 Nov 2026, 02:44 pm

Corporate Events

Board MeetingPGHL
2026
2Nov

Board Meeting

A meeting of the Board of Directors of the Company is schedu…

BSE Filing ↗
DividendPGHL
2026
27Aug

₹45 / share

BSE Filing ↗
Board MeetingPGHL
2026
27Aug

Board Meeting

The 59th Annual General Meeting of the Company is scheduled …

BSE Filing ↗
DividendPGHL
2026
21Aug

₹45 / share

BSE Filing ↗
Board MeetingPGHL
2026
6Aug

Board Meeting

The meeting of the Board of Directors of the Company is sche…

BSE Filing ↗
Board MeetingPGHL
2026
30Jun

Board Meeting

The Board of Directors approved the Unaudited Financial Resu…

BSE Filing ↗
Board MeetingPGHL
2026
26May

Board Meeting

To consider and approve Audited Financial Statements for the…

BSE Filing ↗
Board MeetingPGHL
2026
6Feb

Board Meeting

Update on board meeting, declaration of interim dividend for…

BSE Filing ↗
Board MeetingPGHL
2025
12Feb

Board Meeting

Update on board meeting, consider declaration of interim div…

BSE Filing ↗
DividendPGHL
2024
28Nov

₹60 / share

BSE Filing ↗
Board MeetingPGHL
2024
4Nov

Board Meeting

Consider and approve Unaudited Financial Results for the Qua…

BSE Filing ↗
DividendPGHL
2024
21Aug

₹60 / share

BSE Filing ↗
Board MeetingPGHL
2024
21Aug

Board Meeting

Considering and approving Audited Financial Results and Stat…

BSE Filing ↗
Board MeetingPGHL
2024
2May

Board Meeting

Consider and approve Unaudited Financial Results for the Qua…

BSE Filing ↗
DividendPGHL
2024
14Feb

₹200 / share

BSE Filing ↗
Board MeetingPGHL
2024
6Feb

Board Meeting

Consideration and approval of unaudited Financial Results fo…

BSE Filing ↗
DividendPGHL
2023
14Nov

₹50 / share

BSE Filing ↗
Board MeetingPGHL
2023
3Nov

Board Meeting

Consider and approve the Unaudited Financial Results for the…

BSE Filing ↗